XNASKRYS
Market cap4.51bUSD
Jan 08, Last price
156.67USD
1D
-1.93%
1Q
-9.52%
IPO
1,428.49%
Name
Krystal Biotech Inc
Chart & Performance
P/E
412.18
P/S
88.88
EPS
0.38
Div Yield, %
0.00%
Shrs. gr., 5y
19.89%
Rev. gr., 5y
118.12%
Revenues
51m
Net income
11m
P
CFO
-89m
L-11.70%
Earnings
Feb 24, 2025
Profile
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 50,699 | |||||||
Cost of revenue | 49,525 | 124,251 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 1,174 | (124,251) | ||||||
NOPBT Margin | 2.32% | |||||||
Operating Taxes | 1,965 | 34,048 | ||||||
Tax Rate | 167.38% | |||||||
NOPAT | (791) | (158,299) | ||||||
Net income | 10,932 -107.81% | (139,975) 101.20% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 203,499 | 35,996 | ||||||
BB yield | -5.91% | -1.78% | ||||||
| Debt | ||||||||
Debt current | 2,948 | 1,561 | ||||||
Long-term debt | 14,714 | 16,305 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (576,470) | (365,926) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (88,804) | (100,569) | ||||||
CAPEX | (11,799) | (52,979) | ||||||
Cash from investing activities | 82,638 | (114,083) | ||||||
Cash from financing activities | 202,750 | 35,347 | ||||||
FCF | (27,162) | (208,442) | ||||||
| Balance | ||||||||
Cash | 532,178 | 379,171 | ||||||
Long term investments | 61,954 | 4,621 | ||||||
Excess cash | 591,597 | 383,792 | ||||||
Stockholders' equity | (269,189) | (281,487) | ||||||
Invested Capital | 1,057,398 | 812,608 | ||||||
ROIC | ||||||||
ROCE | 0.15% | |||||||
| EV | ||||||||
Common stock shares outstanding | 27,752 | 25,492 | ||||||
Price | 124.06 56.60% | 79.22 13.25% | ||||||
Market cap | 3,442,889 70.49% | 2,019,454 30.06% | ||||||
EV | 2,866,419 | 1,653,528 | ||||||
EBITDA | 6,181 | (120,196) | ||||||
EV/EBITDA | 463.75 | |||||||
Interest | 5,221 | |||||||
Interest/NOPBT | ||||||||